Table 1 Baseline and endoscopic characteristics of 150 patients with HSV and CMV esophagitis.
|  | HSV (n = 87) | CMV (n = 63) | p value |
|---|---|---|---|
Age (median, IQR) (years) | 59 (24–84) | 61 (24–79) | 0.214 |
Sex (male:female) | 61:26 | 23:40 | 0.393 |
Comorbidity | |||
Malignancies | 34 (39.1) | 22 (34.9) | 0.603 |
 Solid tumor | 27 (31.0) | 19 (30.2) | 0.909 |
 Hematologic malignancy | 7 (8.0) | 3 (4.8) | 0.521 |
Immunosuppressive therapy | |||
 Transplantation | 14 (16.1) | 24 (38.1) | 0.002 |
  Solid organ | 11 (12.6) | 23 (36.5) | 0.001 |
  Hematopoietic stem cell | 3 (3.4) | 1 (1.6) | 0.639 |
 Rheumatologic disease | 6 (6.9) | 2 (3.2) | 0.469 |
HIV infection | 0 | 2 (3.2) | 0.175 |
Diabetes mellitus | 14 (16.1) | 17 (27.0) | 0.139 |
Chronic kidney disease | 4 (4.6) | 3 (4.8) | 1.000 |
Liver cirrhosis | 1 (1.1) | 2 (3.2) | 0.572 |
Steroid user* | 2 (2.3) | 0 | 0.510 |
Corrosive esophagitis | 1 (1.1) | 0 | 1.000 |
No underlying disease | 4 (4.6) | 0 | 0.139 |
Distribution | Â | Â | 0.111 |
Proximal esophagus | 5 (5.7) | 3 (4.8) | 1.000 |
Middle esophagus | 10 (11.5) | 12 (46.0) | 0.197 |
Distal esophagus | 25 (28.7) | 23 (23.8) | 0.314 |
Two or more segments | 47 (54.0) | 25 (39.7) | 0.083 |
Initial diagnosis of endoscopist | |||
HSV esophagitis | 50 (57.5) | 5 (7.9) | Â |
CMV esophagitis | 1 (1.1) | 29 (46.0) | Â |
Indeterminate | 12 (13.8) | 15 (23.8) | Â |
Esophageal cancer | 2 (2.3) | 3 (4.8) | Â |
Candida esophagitis | 11 (12.6) | 3 (4.8) | Â |
Reflux esophagitis | 5 (5.7) | 5 (7.9) | Â |
Non-specific erosion or ulcer | 5 (5.7) | 2 (3.2) | Â |
Radiation-induced esophagitis | 1 (1.1) | 1 (1.6) | Â |
